Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mylan NV Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,958,729
  • Shares Outstanding, K 515,462
  • Annual Sales, $ 11,434 M
  • Annual Income, $ 352,500 K
  • 60-Month Beta 1.73
  • Price/Sales 0.78
  • Price/Cash Flow 2.00
  • Price/Book 0.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.97
  • Number of Estimates 7
  • High Estimate 1.08
  • Low Estimate 0.88
  • Prior Year 1.07
  • Growth Rate Est. (year over year) -9.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.63 +2.35%
on 05/31/19
20.51 -17.02%
on 05/16/19
-3.39 (-16.61%)
since 05/14/19
3-Month
16.63 +2.35%
on 05/31/19
29.30 -41.91%
on 03/21/19
-10.98 (-39.21%)
since 03/14/19
52-Week
16.63 +2.35%
on 05/31/19
39.86 -57.30%
on 06/15/18
-22.49 (-56.92%)
since 06/14/18

Most Recent Stories

More News
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories

Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the expansion of the companies'...

TBPH : 15.95 (-4.83%)
MYL : 17.02 (-2.07%)
Shares of MYL Down 37.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on February 27th, 2019 at $27.53. In approximately 4 months, Mylan Nv has returned 37.20% as of today's recent price of $17.29.

MYL : 17.02 (-2.07%)
Look for Shares of Mylan Nv to Potentially Rebound after Yesterday's 2.40% Sell Off

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $16.92 to a high of $17.25. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $17.20 on...

MYL : 17.02 (-2.07%)
After Yesterday's Decline of 2.40%, Mylan Nv Offers Investors Better Value

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $16.92 to a high of $17.25. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $17.20 on...

MYL : 17.02 (-2.07%)
Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound?

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MYL : 17.02 (-2.07%)
Mylan Nv Shares Down 35.7% Since SmarTrend's Sell Call (MYL)

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on February 27th, 2019 at $27.53. In approximately 3 months, Mylan Nv has returned 35.71% as of today's recent price of $17.70.

MYL : 17.02 (-2.07%)
Teva Settles With Oklahoma, Shares Fall Following Downgrade

Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.

MYL : 17.02 (-2.07%)
JNJ : 140.09 (-0.44%)
UBS : 11.54 (-1.28%)
TEVA : 8.24 (-4.30%)
Amgen (AMGN) Offers to Acquire Drug Discovery Platform

Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

MYL : 17.02 (-2.07%)
LLY : 111.74 (-0.07%)
CHRS : 18.65 (+2.19%)
AMGN : 176.08 (-0.36%)
Shares of MYL Down 28.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Mylan Nv (NASDAQ:MYL) on February 27th, 2019 at $27.53. In approximately 3 months, Mylan Nv has returned 28.15% as of today's recent price of $19.78.

MYL : 17.02 (-2.07%)
After Yesterday's Decline of 1.83%, Mylan Nv Offers Investors Better Value

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $19.26 to a high of $19.30. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $19.40 on...

MYL : 17.02 (-2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade MYL with:

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 17.75
1st Resistance Point 17.38
Last Price 17.02
1st Support Level 16.78
2nd Support Level 16.55

See More

52-Week High 39.86
Fibonacci 61.8% 30.99
Fibonacci 50% 28.24
Fibonacci 38.2% 25.50
Last Price 17.02
52-Week Low 16.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar